Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Medical gains Korean approval for anticancer HIFU (highintensity focused ultrasound) system:

This article was originally published in Clinica

Executive Summary

The highintensity focused ultrasound (HIFU) tumour therapy system developed by Beijing-based China Medical Technologies has received official approval from the Korean FDA. The device is now approved to treat liver and pancreatic cancers and uterine fibroids. The firm received conditional approval to start US-based human trials of the device from the US FDA in July. Cancer is the leading cause of death in Korea.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel